Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma
What is this summary about? - - This is a summary of a clinical trial called MAIA. The trial tested 2 combinations of cancer drugs (daratumumab plus lenalidomide and dexamethasone compared with lenalidomide and dexamethasone) in people with newly diagnosed multiple myeloma. None of the participants...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
Apr 2023
|
| In: |
Future oncology
Year: 2023, Jahrgang: 19, Heft: 13, Pages: 887-895 |
| ISSN: | 1744-8301 |
| DOI: | 10.2217/fon-2023-0082 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.2217/fon-2023-0082 Verlag, kostenfrei, Volltext: https://www.futuremedicine.com/doi/10.2217/fon-2023-0082 
|
| Verfasserangaben: | Thierry Facon, Shaji K Kumar, Torben Plesner, Robert Z Orlowski, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Aurore Perrot, Katja Weisel, Noopur Raje, Margaret Macro, Laurent Frenzel, Xavier Leleu, Jianping Wang, Rian Van Rampelbergh, Clarissa M Uhlar, Jessica Vermeulen, Joana Duran, Fredrik Borgsten & Saad Z Usmani |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1856332322 | ||
| 003 | DE-627 | ||
| 005 | 20240329080240.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230816s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2023-0082 |2 doi | |
| 035 | |a (DE-627)1856332322 | ||
| 035 | |a (DE-599)KXP1856332322 | ||
| 035 | |a (OCoLC)1425212738 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Facon, Thierry |e VerfasserIn |0 (DE-588)142000302 |0 (DE-627)632864079 |0 (DE-576)327295007 |4 aut | |
| 245 | 1 | 0 | |a Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma |c Thierry Facon, Shaji K Kumar, Torben Plesner, Robert Z Orlowski, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Aurore Perrot, Katja Weisel, Noopur Raje, Margaret Macro, Laurent Frenzel, Xavier Leleu, Jianping Wang, Rian Van Rampelbergh, Clarissa M Uhlar, Jessica Vermeulen, Joana Duran, Fredrik Borgsten & Saad Z Usmani |
| 264 | 1 | |c Apr 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 22. Mai 2023 | ||
| 500 | |a Gesehen am 16.08.2023 | ||
| 520 | |a What is this summary about? - - This is a summary of a clinical trial called MAIA. The trial tested 2 combinations of cancer drugs (daratumumab plus lenalidomide and dexamethasone compared with lenalidomide and dexamethasone) in people with newly diagnosed multiple myeloma. None of the participants who took part in the study had been treated before or were eligible to receive stem-cell transplants. - - How was the study in this summary conducted? - - A total of 737 participants took part. Half of the participants took daratumumab plus lenalidomide and dexamethasone, while the other half of the participants took only lenalidomide and dexamethasone. Once participants started taking the drugs, the cancer was monitored for improvement (response to treatment), worsening (disease progression), or no change. Participants' blood and urine were tested for myeloma protein to measure response to the treatment. Participants were also monitored for side effects. - - What were the results of the study? - - After approximately 56 months of follow-up, more participants who took daratumumab plus lenalidomide and dexamethasone were alive and had decreased myeloma protein levels (indicating improvement of cancer) than participants who took only lenalidomide and dexamethasone. The most common side effects were abnormally low white and red blood cell counts and increased lung infections. - - What do the results of the study mean? - - In the MAIA study, participants with multiple myeloma who took daratumumab plus lenalidomide and dexamethasone lived longer and had decreased myeloma protein levels than participants who took only lenalidomide and dexamethasone, indicating survival could be more likely with daratumumab added. - - Clinical Trial Registration:NCT02252172 (Phase 3 MAIA study) | ||
| 650 | 4 | |a CD38 | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a daratumumab | |
| 650 | 4 | |a dexamethasone | |
| 650 | 4 | |a lay summary | |
| 650 | 4 | |a lenalidomide | |
| 650 | 4 | |a monoclonal antibody | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a newly diagnosed multiple myeloma | |
| 650 | 4 | |a plain language summary | |
| 700 | 1 | |a Kumar, Shaji K |e VerfasserIn |4 aut | |
| 700 | 1 | |a Plesner, Torben |e VerfasserIn |4 aut | |
| 700 | 1 | |a Orlowski, Robert Z |e VerfasserIn |4 aut | |
| 700 | 1 | |a Moreau, Philippe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bahlis, Nizar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Basu, Supratik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nahi, Hareth |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hulin, Cyrille |e VerfasserIn |4 aut | |
| 700 | 1 | |a Quach, Hang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Perrot, Aurore |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weisel, Katja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Raje, Noopur |e VerfasserIn |4 aut | |
| 700 | 1 | |a Macro, Margaret |e VerfasserIn |4 aut | |
| 700 | 1 | |a Frenzel, Laurent |e VerfasserIn |4 aut | |
| 700 | 1 | |a Leleu, Xavier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wang, Jianping |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rampelbergh, Rian Van |e VerfasserIn |4 aut | |
| 700 | 1 | |a Uhlar, Clarissa M |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vermeulen, Jessica |e VerfasserIn |4 aut | |
| 700 | 1 | |a Duran, Joana |e VerfasserIn |4 aut | |
| 700 | 1 | |a Borgsten, Fredrik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Usmani, Saad Z |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology |d London : Taylor & Francis, 2005 |g 19(2023), 13 vom: Apr., Seite 887-895 |h Online-Ressource |w (DE-627)484405055 |w (DE-600)2184533-5 |w (DE-576)398100217 |x 1744-8301 |7 nnas |a Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:13 |g month:04 |g pages:887-895 |g extent:9 |a Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma |
| 856 | 4 | 0 | |u https://doi.org/10.2217/fon-2023-0082 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.futuremedicine.com/doi/10.2217/fon-2023-0082 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230816 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 11 | ||
| 999 | |a KXP-PPN1856332322 |e 4366680971 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"Apr 2023","dateIssuedKey":"2023"}],"note":["Online veröffentlicht: 22. Mai 2023","Gesehen am 16.08.2023"],"title":[{"title_sort":"Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma","title":"Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Thierry Facon, Shaji K Kumar, Torben Plesner, Robert Z Orlowski, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Aurore Perrot, Katja Weisel, Noopur Raje, Margaret Macro, Laurent Frenzel, Xavier Leleu, Jianping Wang, Rian Van Rampelbergh, Clarissa M Uhlar, Jessica Vermeulen, Joana Duran, Fredrik Borgsten & Saad Z Usmani"]},"physDesc":[{"noteIll":"Illustrationen","extent":"9 S."}],"recId":"1856332322","relHost":[{"part":{"volume":"19","extent":"9","text":"19(2023), 13 vom: Apr., Seite 887-895","issue":"13","year":"2023","pages":"887-895"},"language":["eng"],"id":{"issn":["1744-8301"],"zdb":["2184533-5"],"eki":["484405055"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"484405055","disp":"Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myelomaFuture oncology","type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title":"Future oncology","title_sort":"Future oncology"}],"note":["Gesehen am 28.05.2024"],"pubHistory":["1.2005 -"],"origin":[{"publisherPlace":"London ; London","publisher":"Taylor & Francis ; Future Medicine Ltd","dateIssuedKey":"2005","dateIssuedDisp":"2005-"}]}],"id":{"doi":["10.2217/fon-2023-0082"],"eki":["1856332322"]},"person":[{"family":"Facon","display":"Facon, Thierry","given":"Thierry","role":"aut"},{"role":"aut","given":"Shaji K","display":"Kumar, Shaji K","family":"Kumar"},{"given":"Torben","role":"aut","display":"Plesner, Torben","family":"Plesner"},{"given":"Robert Z","role":"aut","display":"Orlowski, Robert Z","family":"Orlowski"},{"given":"Philippe","role":"aut","family":"Moreau","display":"Moreau, Philippe"},{"role":"aut","given":"Nizar","display":"Bahlis, Nizar","family":"Bahlis"},{"family":"Basu","display":"Basu, Supratik","role":"aut","given":"Supratik"},{"family":"Nahi","display":"Nahi, Hareth","role":"aut","given":"Hareth"},{"family":"Hulin","display":"Hulin, Cyrille","role":"aut","given":"Cyrille"},{"given":"Hang","role":"aut","display":"Quach, Hang","family":"Quach"},{"family":"Goldschmidt","display":"Goldschmidt, Hartmut","given":"Hartmut","role":"aut"},{"display":"Perrot, Aurore","family":"Perrot","role":"aut","given":"Aurore"},{"family":"Weisel","display":"Weisel, Katja","given":"Katja","role":"aut"},{"display":"Raje, Noopur","family":"Raje","given":"Noopur","role":"aut"},{"role":"aut","given":"Margaret","family":"Macro","display":"Macro, Margaret"},{"family":"Frenzel","display":"Frenzel, Laurent","role":"aut","given":"Laurent"},{"given":"Xavier","role":"aut","display":"Leleu, Xavier","family":"Leleu"},{"role":"aut","given":"Jianping","display":"Wang, Jianping","family":"Wang"},{"given":"Rian Van","role":"aut","family":"Rampelbergh","display":"Rampelbergh, Rian Van"},{"family":"Uhlar","display":"Uhlar, Clarissa M","role":"aut","given":"Clarissa M"},{"display":"Vermeulen, Jessica","family":"Vermeulen","given":"Jessica","role":"aut"},{"display":"Duran, Joana","family":"Duran","given":"Joana","role":"aut"},{"given":"Fredrik","role":"aut","display":"Borgsten, Fredrik","family":"Borgsten"},{"display":"Usmani, Saad Z","family":"Usmani","role":"aut","given":"Saad Z"}],"language":["eng"]} | ||
| SRT | |a FACONTHIERPLAINLANGU2023 | ||